LNP CDMO Market Size to Hit USD 820.46 Million by 2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on LNP CDMO Market

5.1. COVID-19 Landscape: LNP CDMO Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global LNP CDMO Market, By Type of Lipid Nanoparticle (LNP)

8.1. LNP CDMO Market, by Type of Lipid Nanoparticle (LNP)

8.1.1. Cationic Lipid Nanoparticles (CLNP)

8.1.1.1. Market Revenue and Forecast

8.1.2. Anionic Lipid Nanoparticles (ALNP)

8.1.2.1. Market Revenue and Forecast

8.1.3. Neutral Lipid Nanoparticles (NLNP)

8.1.3.1. Market Revenue and Forecast

Chapter 9. Global LNP CDMO Market, By Service Type

9.1. LNP CDMO Market, by Service Type

9.1.1. Drug Development

9.1.1.1. Market Revenue and Forecast

9.1.2. Analytical and Testing Services

9.1.2.1. Market Revenue and Forecast

9.1.3. Formulation Development

9.1.3.1. Market Revenue and Forecast

9.1.4. Fill and Finish Services

9.1.4.1. Market Revenue and Forecast

Chapter 10. Global LNP CDMO Market, By End Use Industry

10.1. LNP CDMO Market, by End Use Industry

10.1.1. Pharmaceutical

10.1.1.1. Market Revenue and Forecast

10.1.2. Biotechnology

10.1.2.1. Market Revenue and Forecast

10.1.3. Cosmetics

10.1.3.1. Market Revenue and Forecast

10.1.4. Agriculture

10.1.4.1. Market Revenue and Forecast

Chapter 11. Global LNP CDMO Market, By Application

11.1. LNP CDMO Market, by Application

11.1.1. mRNA Delivery

11.1.1.1. Market Revenue and Forecast

11.1.2. Gene Therapy

11.1.2.1. Market Revenue and Forecast

11.1.3. Cancer Therapy

11.1.3.1. Market Revenue and Forecast

11.1.4. Vaccine Delivery

11.1.4.1. Market Revenue and Forecast

11.1.5. RNA-based Drugs

11.1.5.1. Market Revenue and Forecast

Chapter 12. Global LNP CDMO Market, By Manufacturing Scale

12.1. LNP CDMO Market, by Manufacturing Scale

12.1.1. Preclinical and Early-Stage Manufacturing

12.1.1.1. Market Revenue and Forecast

12.1.2. Clinical-Stage Manufacturing

12.1.2.1. Market Revenue and Forecast

12.1.3. Commercial-Scale Manufacturing

12.1.3.1. Market Revenue and Forecast

Chapter 13. Global LNP CDMO Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Forecast, by Type of Lipid Nanoparticle (LNP)

13.1.2. Market Revenue and Forecast, by Service Type

13.1.3. Market Revenue and Forecast, by End Use Industry

13.1.4. Market Revenue and Forecast, by Application

13.1.5. Market Revenue and Forecast, by Manufacturing Scale

13.1.6. U.S.

13.1.6.1. Market Revenue and Forecast, by Type of Lipid Nanoparticle (LNP)

13.1.6.2. Market Revenue and Forecast, by Service Type

13.1.6.3. Market Revenue and Forecast, by End Use Industry

13.1.6.4. Market Revenue and Forecast, by Application

13.1.6.5. Market Revenue and Forecast, by Manufacturing Scale

13.1.7. Rest of North America

13.1.7.1. Market Revenue and Forecast, by Type of Lipid Nanoparticle (LNP)

13.1.7.2. Market Revenue and Forecast, by Service Type

13.1.7.3. Market Revenue and Forecast, by End Use Industry

13.1.7.4. Market Revenue and Forecast, by Application

13.1.7.5. Market Revenue and Forecast, by Manufacturing Scale

13.2. Europe

13.2.1. Market Revenue and Forecast, by Type of Lipid Nanoparticle (LNP)

13.2.2. Market Revenue and Forecast, by Service Type

13.2.3. Market Revenue and Forecast, by End Use Industry

13.2.4. Market Revenue and Forecast, by Application

13.2.5. Market Revenue and Forecast, by Manufacturing Scale

13.2.6. UK

13.2.6.1. Market Revenue and Forecast, by Type of Lipid Nanoparticle (LNP)

13.2.6.2. Market Revenue and Forecast, by Service Type

13.2.6.3. Market Revenue and Forecast, by End Use Industry

13.2.7. Market Revenue and Forecast, by Application

13.2.8. Market Revenue and Forecast, by Manufacturing Scale

13.2.9. Germany

13.2.9.1. Market Revenue and Forecast, by Type of Lipid Nanoparticle (LNP)

13.2.9.2. Market Revenue and Forecast, by Service Type

13.2.9.3. Market Revenue and Forecast, by End Use Industry

13.2.10. Market Revenue and Forecast, by Application

13.2.11. Market Revenue and Forecast, by Manufacturing Scale

13.2.12. France

13.2.12.1. Market Revenue and Forecast, by Type of Lipid Nanoparticle (LNP)

13.2.12.2. Market Revenue and Forecast, by Service Type

13.2.12.3. Market Revenue and Forecast, by End Use Industry

13.2.12.4. Market Revenue and Forecast, by Application

13.2.13. Market Revenue and Forecast, by Manufacturing Scale

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Forecast, by Type of Lipid Nanoparticle (LNP)

13.2.14.2. Market Revenue and Forecast, by Service Type

13.2.14.3. Market Revenue and Forecast, by End Use Industry

13.2.14.4. Market Revenue and Forecast, by Application

13.2.15. Market Revenue and Forecast, by Manufacturing Scale

13.3. APAC

13.3.1. Market Revenue and Forecast, by Type of Lipid Nanoparticle (LNP)

13.3.2. Market Revenue and Forecast, by Service Type

13.3.3. Market Revenue and Forecast, by End Use Industry

13.3.4. Market Revenue and Forecast, by Application

13.3.5. Market Revenue and Forecast, by Manufacturing Scale

13.3.6. India

13.3.6.1. Market Revenue and Forecast, by Type of Lipid Nanoparticle (LNP)

13.3.6.2. Market Revenue and Forecast, by Service Type

13.3.6.3. Market Revenue and Forecast, by End Use Industry

13.3.6.4. Market Revenue and Forecast, by Application

13.3.7. Market Revenue and Forecast, by Manufacturing Scale

13.3.8. China

13.3.8.1. Market Revenue and Forecast, by Type of Lipid Nanoparticle (LNP)

13.3.8.2. Market Revenue and Forecast, by Service Type

13.3.8.3. Market Revenue and Forecast, by End Use Industry

13.3.8.4. Market Revenue and Forecast, by Application

13.3.9. Market Revenue and Forecast, by Manufacturing Scale

13.3.10. Japan

13.3.10.1. Market Revenue and Forecast, by Type of Lipid Nanoparticle (LNP)

13.3.10.2. Market Revenue and Forecast, by Service Type

13.3.10.3. Market Revenue and Forecast, by End Use Industry

13.3.10.4. Market Revenue and Forecast, by Application

13.3.10.5. Market Revenue and Forecast, by Manufacturing Scale

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Forecast, by Type of Lipid Nanoparticle (LNP)

13.3.11.2. Market Revenue and Forecast, by Service Type

13.3.11.3. Market Revenue and Forecast, by End Use Industry

13.3.11.4. Market Revenue and Forecast, by Application

13.3.11.5. Market Revenue and Forecast, by Manufacturing Scale

13.4. MEA

13.4.1. Market Revenue and Forecast, by Type of Lipid Nanoparticle (LNP)

13.4.2. Market Revenue and Forecast, by Service Type

13.4.3. Market Revenue and Forecast, by End Use Industry

13.4.4. Market Revenue and Forecast, by Application

13.4.5. Market Revenue and Forecast, by Manufacturing Scale

13.4.6. GCC

13.4.6.1. Market Revenue and Forecast, by Type of Lipid Nanoparticle (LNP)

13.4.6.2. Market Revenue and Forecast, by Service Type

13.4.6.3. Market Revenue and Forecast, by End Use Industry

13.4.6.4. Market Revenue and Forecast, by Application

13.4.7. Market Revenue and Forecast, by Manufacturing Scale

13.4.8. North Africa

13.4.8.1. Market Revenue and Forecast, by Type of Lipid Nanoparticle (LNP)

13.4.8.2. Market Revenue and Forecast, by Service Type

13.4.8.3. Market Revenue and Forecast, by End Use Industry

13.4.8.4. Market Revenue and Forecast, by Application

13.4.9. Market Revenue and Forecast, by Manufacturing Scale

13.4.10. South Africa

13.4.10.1. Market Revenue and Forecast, by Type of Lipid Nanoparticle (LNP)

13.4.10.2. Market Revenue and Forecast, by Service Type

13.4.10.3. Market Revenue and Forecast, by End Use Industry

13.4.10.4. Market Revenue and Forecast, by Application

13.4.10.5. Market Revenue and Forecast, by Manufacturing Scale

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Forecast, by Type of Lipid Nanoparticle (LNP)

13.4.11.2. Market Revenue and Forecast, by Service Type

13.4.11.3. Market Revenue and Forecast, by End Use Industry

13.4.11.4. Market Revenue and Forecast, by Application

13.4.11.5. Market Revenue and Forecast, by Manufacturing Scale

13.5. Latin America

13.5.1. Market Revenue and Forecast, by Type of Lipid Nanoparticle (LNP)

13.5.2. Market Revenue and Forecast, by Service Type

13.5.3. Market Revenue and Forecast, by End Use Industry

13.5.4. Market Revenue and Forecast, by Application

13.5.5. Market Revenue and Forecast, by Manufacturing Scale

13.5.6. Brazil

13.5.6.1. Market Revenue and Forecast, by Type of Lipid Nanoparticle (LNP)

13.5.6.2. Market Revenue and Forecast, by Service Type

13.5.6.3. Market Revenue and Forecast, by End Use Industry

13.5.6.4. Market Revenue and Forecast, by Application

13.5.7. Market Revenue and Forecast, by Manufacturing Scale

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Forecast, by Type of Lipid Nanoparticle (LNP)

13.5.8.2. Market Revenue and Forecast, by Service Type

13.5.8.3. Market Revenue and Forecast, by End Use Industry

13.5.8.4. Market Revenue and Forecast, by Application

13.5.8.5. Market Revenue and Forecast, by Manufacturing Scale

Chapter 14. Company Profiles

14.1. Lonza Group

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. WuXi AppTec

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. Samsung Biologics

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Catalent

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. Moderna

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. Evonik Industries

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. CordenPharma

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. BioNTech

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. Albemarle Corporation

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. Kuehne + Nagel

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The LNP CDMO market size is expected to increase from USD 205.47 million in 2024 to USD 820.46 million by 2034.

The LNP CDMO market is expected to grow at a compound annual growth rate (CAGR) of around 14.85% from 2025 to 2034.

The major players in the LNP CDMO market include Lonza Group, WuXi AppTec, Samsung Biologics, Catalent, Moderna, Evonik Industries, CordenPharma, BioNTech, Albemarle Corporation, Kuehne + Nagel, Northway Biotechpharma, Cryoport, Inc., AMRI, Pharmaron, Genevant Sciences, Miltenyi Biotec, SynBioTech, JHL Biotech, Particle Sciences, Inc., and Acell Technologies.

The driving factors of the LNP CDMO market are the increasing demand for delivery systems, especially in the development of mRNA-based vaccines and therapeutics.

North America region will lead the global LNP CDMO market during the forecast period 2025 to 2034.